Weaving Through the Maze: PDPM, DRR vs. MRR, Quality Measures A Case Study





Maggie Turner, RN RAC-CT

Forrest Moore, pharmD

Lisa Gourley, RN RAC-CT

Learning Objectives

- Understand the impact of timely and accurate ICD-10 and MDS coding related to PDPM
- Recognize the role of pharmacy and the Interdisciplinary team related to drivers of PDPM and Quality Measures
- Distinguish the difference in requirements between DRR and MRR
- Identify critical timing of assessment events from admission to discharge

Resident Profile

- 67 y/o female
- Resided at facility in a Medicare Part A stay with primary diagnosis of Cerebral Infarct then had hospital readmission on 9/24
- Had a Significant Change 5 day assessment completed on 9/20
- Admitted to the hospital on 9/24 on day 12 of Medicare stay
- Readmitted to the facility on 9/28 as a hospital return
 - Medicare Part A (traditional Medicare)
 - Also has Community Health Choices (CHC)
 - New on return to facility: Receiving IV antibiotics, Tracheostomy care, wound care, and Tube Feeding

MDS Assessment Schedule

Type of Assessment		Timing of Assessments Required
Discharge to hospital	-	Discharge Return Anticipated/PPS Discharge with ARD 9/24/19
ReadmissionOBRA vs. PDPM requirements	-	Entry Record 9/28/19 Medicare 5 Day ARD 9/30
Schedule after October 1st	-	PDPM IPA (Interim Payment Assessment) Schedule between 10/1-10/7

Review record for Significant Change

Have 14 days to complete from ARD

Diagnosis

Diagnosis

- Cerebral Infarct
- Right Hemiparesis
- Right Hemiplegia
- Pneumonia
- Epilepsy
- Aphasia
- Dysphasia
- Depression
- Anxiety
- Diabetes
- Pressure Ulcer (Stage IV) Right Heel

ICD-10

- 169.351 Hemiplegia/Hemiparesis following Cerebral Infarction affect right dominant side/stroke/CVA (Acute Neurological)
- J18.9 Pneumonia unspecified organism (Pulmonary)
- G40.919 Epilepsy, unspecified intractable without status without status epilepticus (Medical Management)
- 169.391 Dysphagia following cerebral infarction/stroke/CVA (Acute Neurological)
- 169.320 Aphasia following Cerebral Infarction, CVA (Acute Neurological)
- F33.92 Major Depressive Disorder, recurrent unspecified Depression (Medical Management)
- F41.9 Anxiety Disorder, unspecified (Medical Management)
- F11.9 Type II Diabetes without complication (Medical Management)
- L89.614 Stage 4 Pressure Ulcer right heel (Medical Management)

Diagnoses

After readmission, this resident was given a diagnosis of **COPD** because she was administered Advair and Spiriva while in the hospital.

HOWEVER, she does <u>NOT</u> have COPD – they were administered for the acute pneumonia.



Impact of Proper Diagnoses and Coding

- PDPM
 - Select Primary Diagnosis
 - Physical Therapy, Occupational Therapy and Speech Therapy
 - Must be reason the resident is being skilled
 - Case study resident had Cerebral Infarction, tracheostomy, new tube feeding
 - Most recent hospitalization for pneumonia
 - WHAT IS THE REASON THIS RESIDENT IS BEING SKILLED?
 - Non-Therapy Ancillaries (NTA)
 - Diagnosis and MDS coding impacts NTA Category.
 - Achieved by points from MDS coding
 - Diabetes = 2 points
 - Stage 4 Pressure Ulcer = 1 point
 - Tracheotomy = 1 point
 - Tube feeding = 1 point
 - Total 5 points = 3-5 points = Urban rate \$106.28 and Rural rate \$101.53
 - If one point identified the 6-8 points = \$147.03 and Rural rate \$140.47

What is the primary diagnosis?

- Functional Score 6-9
- Primary diagnosis
 - 69.351 Hemiplegia/Hemiparesis following Cerebral Infarction affect right dominant side/stroke/CVA (Acute Neurological)
 - PT/OT component Non-Orthopedic Surgery and Acute Neurologic
 - Urban Rate \$174.74 unadjusted rate/day
 - Rural Rate \$197.89 unadjusted rate/day
 - Acute Neurological also will place them in Speech component

Speech co-morbidity only requires one condition however, resident has Hemiplegia, dysphagia/aphasia (if not using therapy treatment code) CVA and trach care.

- J18.9 Pneumonia unspecified organism (Pulmonary)
 - PT/OT component Medical Management
 - Urban Rate \$168.27 unadjusted rate/day
 - Rural Rate \$190.56 unadjusted rate/day
- What is this resident being skilled for? Team decision!



- Cefepime I.V. cost (and need for IV access)
 - Cefepime 2gm IV every 8 hours x 10 days (pneumonia)
 - Days 1-3 in hospital; days 4-10 in facility cost of 7 days approx.
 \$700
 - 4th gen cephalosporin; may not be a great candidate for oral conversion if true hospital-acquired pneumonia, but need for IV administration of other meds should be considered
 - A detailed evaluation of hospital course and HPI should be performed to ensure that proper ID protocols were performed when IV antibiotic agent was selected

- Sliding Scale Novolog started in hospital (taken off of Metformin and Humulin-N)
 - Cost per vial of Novolog \$300/vial and cost associated with glucose testing and increased nursing time
 - Started in hospital as part of glycemic protocol; Humulin-N and Metformin were discontinued due to temporary NPO status and poor glucose control





Protonix (PPI) started in hospital for prophylaxis

- Cost of Protonix granules \$115/week
- Are there any clinical indicators that there is still a need?

Santyl to stage-IV right heel ulcer

- Cost per 30gm tube \$300 (multiple tubes necessary for continued treatment)
- Are there other effective treatments that could be utilized?



Cost associated with inappropriately continuing treatment for the inaccurate COPD diagnosis

Financial consideration Ethical consideration

PRN Ativan being used for crying

- Cost associated with therapy the drug is negligible
- Incorrect diagnosis listed for use (anxiety would be correct with crying possibly used for behavior monitoring)
- **PRN psychotropic** subject to recent mega-rule regulation

What's wrong with this scenario?



Zyprexa

- Cost associated with therapy negligible
- Patient started on Zyprexa in hospital due to acute agitation and possible delirium which resolved after antibiotic treatment started
- Continued in skilled care with diagnosis of <u>"antipsychotic"</u>

What's wrong in this scenario?



Inappropriate use reflects directly in short-term quality measures



DVT prevention with **Lovenox**

- Enoxaparin (Lovenox) 40mg sub-Q daily indefinitely; cost of therapy - \$120/wk
- Evaluation of medical need for prophylaxis must be continually weighed
- Converting to oral agent (Eliquis, Xarelto) does not offer great cost savings of medication, but reduces administration burden.
- While cheaper, Warfarin is likely not more cost effective due to increased need for labwork

MRR

- 1974 Medicare requirement that every patient residing in a skilled nursing center receive a monthly review of their medication profile by a licensed pharmacist
- The regulation has expanded to include review of all patient profiles once a month, after admission or readmission, and for any major change in condition (no requirement for time frame is specified)
- CMS definition of MRR is essentially synonymous with DRR for SNFs

DRR

- Defined in the IMPACT Act of 2014
- Includes medication reconciliation and general review of drug regimen to address and prevent "clinically significant" or "potentially significant" medication issues (i.e. major drug interactions, drug allergies, obvious therapeutic duplications or omissions, ineffective or unnecessary therapy, adverse drug reactions)

MRR

- Thorough evaluation of the med regimen with the goal of promoting positive outcomes and minimizing adverse events associated with medications.
- Includes preventing, identifying, reporting, and resolving medicationrelated problems, med errors, or other irregularities.
- All recommendations and consults must be reported to the attending physician and addressed by said physician or designee within 30 days (additionally must be reviewed by medical director and director of nursing)

DRR

- Not specific to being performed by a pharmacist - DRR may be performed by a variety of clinical professionals
- Strict reporting requirement of all clinically or potentially significant medication issues to physician or designee by midnight of the next calendar day after they are identified (after admission or AT ANY TIME during their stay).

DRR

- SNF Quality Reporting Program (QRPs)
- Drug Regimen Review conducted with follow-up for identified issues
- Reports the percentage of Medicare Part A SNF Stays at time of admission and timely follow-up with physician occurred each time potential or actual clinically significant medication issues were identified <u>through out</u> stay.
- Data collection began October 1, 2018
- Includes all medication: prescribed, over the counter, herbal, nutritional supplements, vitamins, homeopathic, Oxygen and TPN.

Consider review of new admission records at morning meeting.

Section N2001 on MDS that is completed on Medicare 5 Day

	1	
N2001. Drug Regimen Review - Complete only if A0310B = 01		
Enter Code	Did a complete drug regimen review identify potential clinically significant medication issues?	
	O. No - No issues found during review 1. Yes - Issues found during review	
	9. NA - Resident is not taking any medications	
N2003. Medication Follow-up - Complete only if N2001 =1		
Did the facility contact a physician (or physician-designee) by midnight of the next calendar day and complete prescribed/recommended actions in response to the identified potential clinically significant medication issues? 0. No 1. Yes		
N2005. Medication Intervention - Complete only if A0310H = 1		
Enter Code	Did the facility contact and complete physician (or physician-designee) prescribed/recommended actions by midnight of the next calendar day each time potential clinically significant medication issues were identified since the admission?	
Ш	O. No 1. Yes	

PPS Discharge

N2005. Medication Intervention - Complete only if A0310H = 1 Enter Code Calendar day each time potential clinically significant medication issues were identified since the admission? O. No O

Can you wait for pharmacy to review for DRR?

- Remember guidance states for DRR that any clinician can review
- What happens when pharmacy contacts the facility with identified issues?
- What is the follow up with issues that are identified?
- Consider review of new admission records at morning meeting

Therapy and Treatments Ordered

The resident is ordered the following:

- Speech Therapy
- Occupational Therapy
- Respiratory Therapy
- Accuchecks tid
- Continuous tube feeding over 20 hours with Glucerna
- Wound Care
 - Santyl
 - Allevyn

MDS Impact of Treatment Plan PDPM/CHC

- Therapy minutes are not necessary to receive Physical Therapy,
 Occupational Therapy or Speech Therapy
- Therapy delivery of service is still an important part of discharge planning
- However, Facilities continue to submit the Facility Quarterly CMIs
 - What are your contracts with CHC?
 - If your CHC contract is set with quarterly CMIs then the rate does change based on that quarterly CMI

MDS Impact of Treatment Plan PDPM/CHC

- Treatment plan should not change with implementation of PDPM or CHC.
- PDPM only changes the payment structure for Medicare Part A residents and those Medicare Replacement Plans that are transitioning to PDPM
 - Do you know which ones will be which???
- Quality Reporting Program Measure only on traditional Medicare Part A

Medicare Skilling Reason Unchanged Chapter 8 Medicare Manual

- NO CHANGE IN MEDICARE PART A COVERAGEMEDICARE BENEFIT POLITY MANUAL CHAPTER 8 —COVERAGE OF EXTENDED CARE (SNF) SERVICES
- Patient requires skilled nursing services or skilled rehabilitation services
- 2. The patient requires these skilled services on a daily basis
- The daily skilled services can be provided only on an inpatient basis in a SNF
- 4. The services delivered are reasonable and necessary for the treatment of a patient's illness or injury

Other Items to Consider

Is your software updated for PDPM?

Is your team aware of October 1 changes?

 Do you know which managed care insurers will be utilizing PDPM vs. RUGs?

Resources

- www.CMS.gov
- https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/NursingHomeQualityInits/Skilled-Nursing-Facility-Quality-Reporting-Program/SNF-Quality-Reporting-Program-Training.html
- MDS-30-RAI-Manual-v117 October-2019
- Medicare Manual Chapter 8